These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21391487)

  • 1. Development and validation of a stability-indicating high-performance liquid chromatography method for the simultaneous determination of albuterol, budesonide, and ipratropium bromide in compounded nebulizer solutions.
    Blewett AJ; Varma D; Gilles T; Butcher R; Jacob J; Amazan J; Jansen SA
    J AOAC Int; 2011; 94(1):110-7. PubMed ID: 21391487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a stability indicating RP-HPLC method for the simultaneous determination of related substances of albuterol sulfate and ipratropium bromide in nasal solution.
    Kasawar GB; Farooqui M
    J Pharm Biomed Anal; 2010 May; 52(1):19-29. PubMed ID: 20045275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-performance liquid chromatographic assay for the simultaneous determination of ipratropium bromide, fenoterol, salbutamol and terbutaline in nebulizer solution.
    Jacobson GA; Peterson GM
    J Pharm Biomed Anal; 1994 Jun; 12(6):825-32. PubMed ID: 7918785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers.
    Kamin W; Schwabe A; Krämer I
    J Cyst Fibros; 2006 Dec; 5(4):205-13. PubMed ID: 16678502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicochemical compatibility of fluticasone-17- propionate nebulizer suspension with ipratropium and albuterol nebulizer solutions.
    Kamin W; Schwabe A; Krämer I
    Int J Chron Obstruct Pulmon Dis; 2007; 2(4):599-607. PubMed ID: 18268934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects on aerosol performance of mixing of either budesonide or beclomethasone dipropionate with albuterol and ipratropium bromide.
    Melani AS
    Respir Care; 2011 Mar; 56(3):319-26. PubMed ID: 21255509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.
    Donohue JF; Wise R; Busse WW; Garfinkel S; Zubek VB; Ghafouri M; Manuel RC; Schlenker-Herceg R; Bleecker ER
    BMC Pulm Med; 2016 Apr; 16(1):65. PubMed ID: 27130202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compatibility of budesonide inhalation suspension with four nebulizing solutions.
    McKenzie JE; Cruz-Rivera M
    Ann Pharmacother; 2004 Jun; 38(6):967-72. PubMed ID: 15084687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary deposition.
    Johnson MA; Newman SP; Bloom R; Talaee N; Clarke SW
    Chest; 1989 Jul; 96(1):6-10. PubMed ID: 2525460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group.
    Chest; 1997 Dec; 112(6):1514-21. PubMed ID: 9404747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of flow pattern, device and formulation on particle size distribution of nebulized aerosol.
    Hu J; Zhang R; Beng H; Deng L; Ke Q; Tan W
    Int J Pharm; 2019 Apr; 560():35-46. PubMed ID: 30664994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical and physical compatibility of levalbuterol inhalation solution concentrate mixed with budesonide, ipratropium bromide, cromolyn sodium, or acetylcysteine sodium.
    Bonasia PJ; McVicar WK; Bill W; Ong S
    Respir Care; 2008 Dec; 53(12):1716-22. PubMed ID: 19025708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions.
    Akapo S; Gupta J; Martinez E; McCrea C; Ye L; Roach M
    Ann Pharmacother; 2008 Oct; 42(10):1416-24. PubMed ID: 18780805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physicochemical compatibility of nebulizable drug mixtures containing dornase alfa and ipratropium and/or albuterol.
    Krämer I; Schwabe A; Lichtinghagen R; Kamin W
    Pharmazie; 2007 Oct; 62(10):760-6. PubMed ID: 18236781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a rapid and validated stability-indicating UPLC-PDA method for concurrent quantification of impurity profiling and an assay of ipratropium bromide and salbutamol sulfate in inhalation dosage form.
    Kondra S; Pawar AKM; Bapuji AT; Shankar PDS
    Ann Pharm Fr; 2023 Mar; 81(2):300-314. PubMed ID: 36126754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, comparative trial of standard and breath-actuated nebulizer: efficacy, safety, and satisfaction.
    Arunthari V; Bruinsma RS; Lee AS; Johnson MM
    Respir Care; 2012 Aug; 57(8):1242-7. PubMed ID: 22348319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma.
    Gelb AF; Karpel J; Wise RA; Cassino C; Johnson P; Conoscenti CS
    Pulm Pharmacol Ther; 2008 Aug; 21(4):630-6. PubMed ID: 18403223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R; Make B
    COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preservatives in nebulizer solutions: risks without benefit.
    Beasley R; Fishwick D; Miles JF; Hendeles L
    Pharmacotherapy; 1998; 18(1):130-9. PubMed ID: 9469687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New ipratropium formulation to decrease nebulization time.
    Majoral C; Vecellio L; Grimbert D; de Monte M; le Guellec C; Ingremeau V; Minois C; Cordeau E; Paintaud G; Steinberg A; Diot P
    Respir Med; 2007 Feb; 101(2):237-45. PubMed ID: 16854578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.